

1 **Sequencing from leftover material of stored rapid Ag Tests (Ag-RDTs): a**
2 **gamechanger in genomic surveillance?**

3

4 Annabel Rector¹, Mandy Bloemen¹, Gilberte Schiettekatte³, Piet Maes¹, Marc Van Ranst^{1,2}
5 and Elke Wollants^{1*}

6

7 ¹KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation,
8 Laboratory of Clinical and Epidemiological Virology, 3000 Leuven, Belgium.

9 ²University Hospitals Leuven, Department of Laboratory Medicine, National Reference Center for
10 Respiratory Pathogens, 3000 Leuven, Belgium.

11 ³ Center for Medical Analysis, Departement of Molecular Biology and Immunology, 2200 Herentals,
12 Belgium

13

14

15

16 *Corresponding author: elke.wollants@kuleuven.be ; +32 16 32 13 41; Herestraat 49 box 1040,
17 BE3000 Leuven, Belgium

18

19 ORCID: Annabel Rector (0000-0003-3714-449X); Mandy Bloemen (0000-0002-3395-0462); Piet Maes
20 (0000-0002-4571-5232); Marc Van Ranst (0000-0002-1674-4157); Elke Wollants (0000-0002-4057-
21 2236).

22

23

24 **ABSTRACT**

25 Archived lateral flow antigen-detection rapid diagnostic tests (Ag-RDTs), used in the diagnosis of
26 COVID-19, were successfully used to extract viral nucleic acids for subsequent RT-qPCR and
27 sequencing by Sanger or Nanopore whole genome sequencing (WGS). The method was successfully
28 applied with different brands of SARS-CoV-2 Ag-RDTs, but also with Ag-RDTs for detection of
29 influenza, rotavirus and adenovirus 40/41. The buffer used in the Ag-RDT had an important influence
30 on the RNA yield from the test strip and the efficiency of subsequent sequencing. Our finding that the
31 test strip in rapid Ag tests is suited to preserve viral genomic material, even for months at room
32 temperature, and therefore can serve as source material for genetic characterization, could improve
33 global coverage of genomic surveillance for SARS-CoV-2 as well as for other viruses.

34

35 **KEY WORDS**

36 Rapid antigen test (Ag RDT), SARS-CoV-2, influenzavirus, adenovirus, rotavirus, Sanger sequencings,
37 whole genome sequencing, genomic surveillance.

38

39 **INTRODUCTION**

40 With over half a billion cases and more than 6 million reported COVID-19 deaths since its emergence
41 in December 2019 [1], the COVID-19 pandemic caused by SARS-CoV-2 has brought on major
42 challenges to health care systems and authorities worldwide. The availability of effective and safe
43 vaccines is without question an important element in our way out of this crisis. Nevertheless, the
44 current COVID-19 vaccines are not sufficient to prevent spread and circulation of the virus, even in
45 highly vaccinated populations [2], and are regrettably not accessible for the entire global population
46 [3]. Therefore, epidemiological surveillance through timely and adequate diagnostic testing for SARS-

47 CoV-2 to guide preventive measures for the control of COVID-19 will remain vital in the battle against
48 the virus.

49 Currently, two types of tests are being used in the diagnosis of SARS-CoV-2 infection. Molecular
50 assays based on the detection of viral RNA through a nucleic acid amplification test (NAAT), such as
51 real-time reverse transcription quantitative PCR (RT-qPCR), are highly sensitive and specific, but in
52 most cases require expensive laboratory facilities and trained technicians, making them less suited
53 for fast scaling-up. An alternative is the detection of viral antigens through immunodiagnostic
54 techniques such as lateral flow antigen-detection rapid diagnostic tests (Ag-RDTs) that can be visually
55 read or processed and read by an instrument. These Ag-RDTs can be performed outside the
56 laboratory, provide a faster result (15 min) and can be produced much faster, cheaper and in large
57 quantities, allowing for swift upscaling of testing capacity. They can be highly specific, but are
58 generally not as sensitive as molecular tests, making them effective for identifying infected persons
59 displaying high virus shedding, who are hence most infectious [4], [5].

60 Although laboratory-based NAAT is still considered to be the reference standard for SARS-CoV-2
61 diagnosis, the WHO recommends the use of Ag-RDTs as a decentralizable, faster and reliable option,
62 provided that the tests meet the WHO standards for Ag-RDTs ($\geq 80\%$ sensitivity and $\geq 97\%$ specificity
63 among symptomatic individuals) [6], [7].

64 The continuous evolution of SARS-CoV-2 has already resulted in the emergence of several variants of
65 interest (VOI) and of concern (VOC) which can be associated with increased transmissibility and/or
66 immune escape [8], [9]. Therefore, genomic surveillance to allow early identification, detection,
67 monitoring and reporting of emerging variants can be considered to be equally important as
68 epidemiological surveillance in achieving effective mitigation and containment of the virus.
69 Moreover, virus whole genome sequences can be used to investigate spatiotemporal spread and
70 transmission routes, and can help in the design of diagnostic assays, antivirals and vaccines [10]–[12].

71 Genomic surveillance of SARS-CoV-2 can be achieved by complete genome sequencing (the golden
72 standard) or by detection of spike protein mutations that are indicative for specific variants through
73 sequencing of a limited region of interest within the receptor binding domain (RBD) of the viral
74 genome [13], [14]. These techniques require the retrieval of viral genetic material from a patient
75 sample, classically the leftover of a nasopharyngeal sample used for NAAT.

76 Based on our previous experience with the preservation and transport of viral material on paper
77 strips [15]–[18], we wanted to test whether the leftover viral material in the cellulose carrier in the
78 test strips used in SARS-CoV-2 Ag-RDTs is sufficient to allow extraction of intact viral nucleic acids and
79 subsequent RT-qPCR, Sanger sequencing and/or whole genome sequencing (WGS).

80 Several other viruses are also frequently diagnosed with Ag-RDTs, and also in these cases obtaining
81 supplementary information regarding the type or variant through sequencing can be of importance.

82 Genomic surveillance of influenza viruses is being performed by labs worldwide within the
83 framework of the WHO's Global Influenza Surveillance and Response System (GISRS). They provide
84 essential information regarding efficacy of vaccines and antiviral drugs against currently circulating
85 influenza viruses, vaccine strain selection and the potential spill-over of animal influenza viruses to
86 humans. The surveillance of circulating genotypes of rotavirus is of crucial importance for detection
87 of novel emerging genotypes and/or antigenic drift of strains that can occur through vaccination and
88 can lead to decreased efficacy or failure of vaccines. For the cases of hepatitis of unknown etiology
89 among young children that were under investigation by ECDC at the time of writing [19], an
90 association with a (novel variant of) human adenovirus 41 (Adv41) is being considered [20], [21].

91 Typing of positive adenovirus samples can therefore be of clinical and epidemiological relevance.

92 In this study, we evaluate the possibility to retrieve leftover material of several viruses from a range
93 of Ag-RDTs, and after longterm storage at room temperature, for use in molecular genetic analysis.

94

95 MATERIALS AND METHODS

96 *Samples*

97 For an optimal result, Ag tests need to be performed with fresh samples containing live virus. Since it
98 was not feasible to perform all Ag tests immediately on infected patients, with sampling using the
99 swab provided by the supplier, we used anonymized stored nasopharyngeal patient samples as a
100 proxy. For use on an Ag-RDT, samples need to be stored in PBS and not in inactivated medium such
101 as zymo, inactive blue or any other virus-inactivating medium that denatures proteins, since Ag-RDTs
102 detect intact viral proteins.

103 Our laboratory functions as the Belgian national reference center (NRC) for coronaviruses,
104 adenoviruses and rotaviruses. The positive samples and positive Ag-RDTs used in this study were
105 anonymized leftover materials of diagnostic samples, tested by the NRC. The use of patients' residual
106 materials by the NRC was approved by the UZ Leuven Ethics Committee.

107 *Rapid Ag tests (Ag-RDTs)*

108 SARS-CoV-2 Ag-RDTs that were used in this study are: Roche SARS-CoV-2 Rapid Antigen Test Nasal,
109 Roche Diagnostics, Basel, Switzerland, Ref. 9901-NCOV-01G and 9901-NCOV-06G (**Roche nasal**);
110 FlowFlex SARS-CoV-2 Antigen Rapid Test (Self-Testing), Acon Laboratories Inc., San Diego, CA, USA,
111 Ref. L031-118P5 (**FlowFlex**); Newgene COVID-19 Antigen Detection Kit – Nasal Swab, Newgene
112 Bioengineering, Hangzhou, China, Ref. COVID-19-NG21 (**Newgene**); Coris COVID-19 Ag K-SeT, Coris
113 BioConcept, Gembloux, Belgium, Ref. K-1525 (**Coris COVID-19**); Alltest: nasal swab test, Hangzhou
114 Alltest Biotech Co. Ltd., Hangzhou, China, Ref. INCP-502-N (**Alltest**); Boson Rapid SARS-CoV-2 Antigen
115 Test Card, Xiamen Boson Biotech Co., Ltd., Xiamen, China, Ref. 1N40C5-2 (**Boson**). SARS-CoV-2 /
116 Influenza dual Ag tests that were used are: Orient Gene Influenza & COVID-19 Ag Combo Rapid Test
117 Cassette, Zhejiang Orient Gene Biotech Co., Ltd, Zhejiang, China, Ref. GCFC-525a (**Orient**); AMP
118 Rapid Test CoV-2 Ag + Flu A+B, AMEDA Labordiagnostik GmbH, Graz, Austria, Ref. RT2962 (**AMP**);
119 Nadal COVID-19 Ag+Influenza A/B plus test, Nal von minden GmbH, Moers, Germany, Ref. 243204N-

120 20 (**Nadal**). For Adenovirus 40/41 and Rotavirus dual Ag test we used the Coris GastroVir K-SeT, Coris
121 BioConcept, Gembloux, Belgium, Ref. K-1516 (**Coris Gastro**). Tests are referred in Table 1 as indicated
122 in bold after every test.

123 Direct testing of patients with the Ag-RDTs was done as described in the test instruction manual. For
124 testing of different Ag-RDTs with positive samples of known viral loads, nasopharyngeal swabs in PBS
125 that had been stored at 4°C were used. Hundred µl of the PBS solution was mixed with the buffer
126 included in the test kit. The Ag-RDT test was further performed as described in the test instructions
127 manual. To assess the effect of the Ag-RDT test buffer on nucleic acid yield, we also performed Ag-
128 RDT tests without using the buffer solution, by transferring 100 µL of PBS solution directly on to the
129 sample window of the test cassette. Ag-RDTs run with PBS without patient sample were used as
130 negative controls.

131 ***Nucleic acid extraction from Ag-RDT test strips***

132 Ag-RDT cassettes were opened by removing the cover, the test strip was taken out and different
133 parts of the test strip were excised with scissors as indicated in Fig. 1.

134 Punch biopsies were taken from unopened Ag-RDT cassettes at the zone of the sample window and
135 at the zone of the positive test line, by using a 2 mm diameter sterile disposable biopsy punch (KAI
136 medical disposable biopsy punch Ref. BP-20F). The biopsy or excised part of the Ag-RDT test strip was
137 directly added to 275 µL lysis buffer in a 96 well lysis plate for extraction with the MagMAX
138 Viral/Pathogen II Nucleic Acid Isolation Kit (ThermoFisher Scientific), according to the protocol for
139 KingFisher Flex.

140 ***Detection of SARS-CoV-2 and Influenza with RT-qPCR***

141 To detect SARS-CoV-2, an RT-qPCR targeting a region in the N2 gene was performed on the
142 QuantStudio™ 7 Flex Real Time PCR system (Applied Biosystems, ThermoFisher). To amplify the N
143 gene region, a reaction mix was made using 5 µL TaqMan™ Fast Virus 1-step Master Mix (Applied

144 Biosystems, Cat 4444434), 1.5 µL primer/probe mix from the 2019-nCoV CDC EUA kit (IDT, Cat
145 10006606) supplemented with 8.5 µL RNase free water to a total volume of 15 µL.

146 For Influenza qPCR a reaction mix was made using 5 µL TaqMan™ Fast Virus 1-step Master Mix
147 (Applied Biosystems, Cat 4444434) with 0.12 µL forward primer (INFA-3)
148 5'TCTCATGGAATGGCTAAAGACAAG-3' (50µM) together with 0.2 µL probe (INFA-FP) FAM-5'-
149 TTCACGCTCACCGTGC-3'-MGB (20µM) and 0.12 µL reverse primer (INFA-2) 5'-
150 CAAAGCGTCTACGCTGCAGT-3' (50µM) supplemented with 9.56 µL RNase free water to a total
151 volume of 15 µL.

152 Five µL of viral RNA was added to the reaction mixes. Thermal cycling conditions were 5 minutes at
153 50°C, 2 minutes at 95°C, followed by 45 cycles of 3 seconds at 95°C and 30 seconds at 60°C. Analysis
154 was done using the QuantStudio Real-Time PCR Software (Applied Biosystems, ThermoFisher).

155 ***Sanger sequencing for virus typing***

156 Sanger sequencing was performed as described in Bloemen et al., 2022 with SARS-CoV-2 primers (S-
157 VOC-F/S-VOC-R). Additional primers for partial sequencing of influenzavirus
158 (AM_FW151/AM_RV397) were described by Schweiger et al., for adenovirus (F-hex1deg/R-hex2deg)
159 by Allard et al. and for rotavirus (F-BEG9/R-END9) by Gouvea et al. [22]–[24].

160 ***Complete genomic sequencing of SARS-CoV-2***

161 Complete genome sequencing of SARS-CoV-2 on RNA extracted from the Ag-RDT was done with the
162 nanopore technique using the ARTIC protocol as described in Wawina-Bokalanga et al. [25].
163 Sequences were analyzed with Nexclade v 2.0.0 (<https://clades.nextstrain.org>)

164

165 **RESULTS**

166 ***Sequencing of SARS-CoV-2 from archived Ag-RDT***

167 A positive SARS-CoV-2 Ag-RDT (SARS-CoV-2 Rapid Antigen Test Nasal, Roche, Ref. 9901-NCOV-06G),
168 that had been used according to the test kit instructions to test an infected patient and was kept for
169 documentation purposes, had been stored at room temperature and not shaded from sunlight for 3
170 months. As a proof of concept, we tested whether residual viral genetic material could be extracted
171 from the test strip. On this strip, the positive test line was still clearly visible, and extraction was done
172 on the positive test strip zone of the test (zone d, indicated in Fig. 1). SARS-CoV-2 RNA could still be
173 detected by RT-q-PCR, with a Ct value of 27.6. Sanger sequencing on the extracted material allowed
174 to unambiguously determine the virus variant as Omicron BA.1, based on the partial sequence of the
175 S-gene RBD (Table 1).

176 We subsequently applied the same method to a Newgene SARS-CoV-2 Ag RDT that had been run
177 with leftover material of a positive nasopharyngeal swab sample, and was stored under the same
178 conditions, and were able to perform complete viral typing by WGS. Likewise, viral material could be
179 retrieved and sequenced from archived SARS-CoV-2/influenza dual Ag-RDTs that had been run with
180 positive nasopharyngeal swab samples (Table 1).

181 ***Evaluation of specimen preparation***

182 The lateral flow rapid Ag tests used in this study all contain a test strip on which the sample is added
183 via the test window. The sample is absorbed onto the sample pad of the test strip, and is transported
184 via capillary flow to the distal end of the strip, flowing over the conjugate pad, test line and control
185 line. To investigate in which area of the test strip the largest amount of viral material from the
186 sample is maintained, and is thus best suited to be used to extract viral material, different zones of
187 the test strip were excised with scissors and used for nucleic acid extraction and RT-qPCR (Fig. 1). A
188 dual antigen test for influenza and COVID-19 (AMP Rapid Test CoV-2 Ag + Flu A+B) that had been run
189 with an influenza positive sample and a SARS-CoV-2 positive sample, was used for nucleic acid
190 extraction 3 months after the Ag test was run. The viral nucleic acid yield at different positions was
191 determined by RT-qPCR for influenza A and SARS-CoV-2 respectively (Table 1: CM-22-1177, CM-22-

192 6381). At all positions that were tested, viral genomic material could be harvested, with the sample
193 pad resulting in the highest yield for both SARS-CoV-2 and influenza, and the zone distal from the
194 test line giving the lowest yield for both viruses. We were able to successfully perform Sanger
195 sequencing on all extracts.

196 To evaluate the possibility of performing extraction from Ag-RDTs in a high throughput environment,
197 we also tested the use of a punch biopsy sample taken at the test line of the strip. These punch
198 biopsies can be picked without opening the test cassette. The use of a punch biopsy versus excision
199 of the test line zone of the strip was compared using a Coris COVID-19 Ag test, and the resulting Ct
200 value were approximately the same (Table 1: CM-22-8672). Since the biopsy procedure can be
201 standardized and is relatively easy to use, we decided to use punch biopsies in further experiments.

202 To evaluate whether viral material is conserved at a comparable degree in different brands of SARS-
203 CoV-2 Ag-RDTs, tests that were commonly used in Belgium at the time of this investigation were run
204 in parallel using the same positive sample (Ct of 18.5). This resulted in a clear positive test line on all
205 tests that were analyzed. Twenty-four hours after performing the Ag test, a punch biopsy was taken
206 from the test line zone and the sample pad of the test strip and used for extraction, followed by RT-
207 qPCR, Sanger sequencing and WGS. All brands of SARS-CoV-2 Ag-RDTs that were tested allowed
208 detection of SARS-CoV-2 by RT-qPCR in the punch biopsy, and in all cases variant typing by Sanger
209 sequencing was possible (Table 1: CM-22-8702). This indicates that conservation of viral material in a
210 used Ag-RDT did not only occur in one specific brand, and that SARS-CoV-2 Ag-RDTs in general can be
211 used for genomic surveillance. We did however notice quite extensive differences in the RNA yield
212 that could be obtained, as indicated by the SARS-CoV-2 Ct value after extraction. Samples extracted
213 from Alltest, Newgene and Boson resulted in WGS data of good quality whereas the FlowFlex sample
214 was typable by WGS but data quality was poor.

215 Since the Ag-RDTs use buffers with different compositions, the effect of the buffer on RNA yield was
216 tested. Samples were loaded on an Ag test with and without addition of the test kit buffer (Table 1,

217 test performed on Roche nasal). For all samples tested, the Ct value of the extract was around 10
218 points higher when buffer was used, which equals approximately a 1000-fold lower concentration of
219 viral genomic material. In general, the results of Sanger sequencing were successful when no buffer
220 was used and good data quality was obtained by WGS. This indicates that some buffer components
221 are deleterious for the viral genetic material, resulting in lower RNA concentrations and interfering
222 with sequencing. WGS was not performed on samples that failed for Sanger sequencing given the
223 high cost of nanopore sequencing.

224 ***Retrieval of viral material of influenza virus, adenovirus and rotavirus from Ag-RDTs***

225 An influenza A virus positive sample (nasopharyngeal swab in viral transport medium), that was
226 tested in the routine diagnostic lab of the NRC, had been run on the influenza test strip of the AMP,
227 Orient and Nadal SARS-CoV-2/influenzavirus dual antigen tests. A positive test line for influenza A
228 was obtained with all three Ag tests. Three months after performing the Ag test, the test line zone
229 was excised with scissors, and viral material was extracted. After extraction, sequences of influenza A
230 could be retrieved by Sanger sequencing of part of the M gene for all three Ag tests.

231 Two fecal samples that were positive for both adenovirus and rotavirus by a routine diagnostic test in
232 the NRC lab were run on Coris GastroVir K-SeT rapid Ag tests. One sample displayed a positive test
233 line for both adeno- and rotavirus on the strip, while the other sample displayed a positive test line
234 for rotavirus but not for adenovirus. Punch biopsies were taken from the sampling pad, the rota test
235 line and the adeno test line of the strips. After extraction of these biopsies, PCR and Sanger
236 sequencing in the VP7 gene was performed for rotavirus detection. For both samples we detected
237 the presence of rotavirus G2 in extractions of the biopsies taken at all 3 sampling sites of the test
238 strip. The adenovirus PCR was also positive for both samples, and sequences of adenovirus 41 were
239 retrieved, again at all 3 sampling sites of the test strip, also in the sample that did not display a
240 positive test band.

241

242

243

244 **DISCUSSION**

245 Whereas RT-qPCR continues to be the gold standard for COVID-19 diagnosis, rapid Ag-RDTs are
246 widely used since they offer the benefit of a very short time to results, are cheaper, and easy to use.
247 A disadvantage of testing through Ag-RDTs so far was that no leftover sample material was available
248 for genomic characterization of positive samples. Our finding that the test strip used in rapid Ag tests
249 are suited to preserve intact viral genomic material, even for months, and can serve as source
250 material for genomic characterization of the virus, could be a gamechanger in the COVID-19 testing
251 strategy.

252 We demonstrated that a SARS-CoV-2 Ag-RDT that was stored at room temperature up to 3 months
253 could still serve as source material for genomic surveillance. This implies that used Ag test can be
254 easily sent to sequencing facilities, even by regular mail. This provides an easy and cheap way to
255 establish baseline genomic surveillance in countries/regions with limited resources, which would
256 otherwise remain blind spots thus allowing for novel virus variants to remain under the radar. This
257 could therefore mean an important improvement in the global coverage of genomic surveillance.

258 In this study, we have tested a total of 9 different Ag-RDTs for SARS-CoV-2 detection (with or without
259 concurrent influenza detection), and were able to successfully perform Sanger sequencing on
260 extracted material from all of these. The difference between the original Ct in the sample and the Ct
261 value after extraction of the test strip largely differed depending on the Ag-RDT used. Our results
262 indicated that the buffer used by some Ag tests contains a chemical compound that breaks down the
263 viral RNA and has a negative effect on the quality of sequencing data. For instance, in case of the
264 Roche nasal test, use of the test kit buffer resulted in a much lower viral RNA yield and made the
265 extract unusable for sequencing. Use of the same Ag test when putting the samples directly on the

266 cassette (without buffer) resulted in much better yields and good sequencing results, both by Sanger
267 and by WGS.

268 Nazario-Toole et al. demonstrated recently that whole genome sequencing of SARS-CoV-2 from
269 excess clinical specimens processed using the BinaxNOW™ COVID-19 Ag Card was feasible [26]. They
270 however did not assess the effect of prolonged room temperature storage of completed Ag cards,
271 nor did they study different brands of SARS-CoV-2 Ag-RDTs, or Ag-RDTs for other viruses.

272 We have shown that this method is more widely useable, by demonstrating that genomic material of
273 influenza virus, adenovirus and rotavirus can also be retrieved from rapid Ag tests. Especially during
274 the upcoming winter seasons, when an upsurge in COVID-19 is to be expected with concomitant
275 circulation of other respiratory pathogens such as influenza virus, the use of Ag-RDTs that allow
276 combined detection of multiple respiratory pathogens, such as COVID-Flu a/b combo tests, can prove
277 to be a very cost-efficient testing strategy. We have now shown that the use of these Ag tests can be
278 combined with genomic surveillance, which will remain equally important in the monitoring of novel
279 variants.

280 We were able to confirm the usability for 10 commercial Ag-RDTs which are commonly used in
281 Belgium. Since it was not possible to test all commercial Ag-RDTs, a validation experiment for each
282 brand and with use of different buffer compositions should be performed prior to large scale
283 implementation of a certain Ag-RDT in genomic surveillance. We plan to further optimize the method
284 for high-throughput processing.

285

286 **ACKNOWLEDGEMENTS**

287 UZ Leuven, as national reference centre, is supported by Sciensano, which is gratefully
288 acknowledged.

289

290 REFERENCES

- 291 [1] WHO, “WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
292 With Vaccination Data.” [Online]. Available: <https://covid19.who.int/>. [Accessed: 16-May-
293 2022].
- 294 [2] J. R. Marcelin, A. Pettifor, H. Janes, E. R. Brown, J. G. Kublin, and K. E. Stephenson, “COVID-19
295 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective,”
296 *Open Forum Infect. Dis.*, 2022.
- 297 [3] V. Pilkington, S. M. Keestra, and A. Hill, “Global COVID-19 Vaccine Inequity: Failures in the
298 First Year of Distribution and Potential Solutions for the Future,” *Front. Public Heal.*, vol. 10,
299 no. March, pp. 1–8, 2022.
- 300 [4] V. M. Corman *et al.*, “Comparison of seven commercial SARS-CoV-2 rapid point-of-care
301 antigen tests: a single-centre laboratory evaluation study,” *The Lancet Microbe*, vol. 2, no. 7,
302 pp. e311–e319, 2021.
- 303 [5] N. Kohmer *et al.*, “Article the comparative clinical performance of four SARS-CoV-2 rapid
304 antigen tests and their correlation to infectivity in vitro,” *J. Clin. Med.*, vol. 10, no. 2, pp. 1–11,
305 2021.
- 306 [6] WHO, “Antigen-detection in the diagnosis of SARS-CoV-2 infection,” *Interim Guid.*, no. 6
307 October, 2021.
- 308 [7] WHO, “Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing,”
309 *Interim Guid.*, no. 9 March, pp. 1–16, 2022.
- 310 [8] WHO, “Tracking SARS-CoV-2 variants.” [Online]. Available:
311 <https://www.who.int/activities/tracking-SARS-CoV-2-variants>. [Accessed: 16-May-2022].
- 312 [9] ECDC, “SARS-CoV-2 variants of concern as of 12 May 2022.” [Online]. Available:

- 313 <https://www.ecdc.europa.eu/en/covid-19/variants-concern>. [Accessed: 16-May-2022].
- 314 [10] J. D. Robishaw *et al.*, “Genomic surveillance to combat COVID-19: challenges and
315 opportunities,” *The Lancet Microbe*, vol. 2, no. 9, pp. e481–e484, 2021.
- 316 [11] WHO, “Recommendations For National SARS-Cov-2 Testing Strategies And Diagnostic
317 Capacities,” *Interim Guid.*, no. June 25, pp. 1–16, 2021.
- 318 [12] WHO, *Genomic sequencing of SARS-CoV-2*, no. January 8. 2021.
- 319 [13] A. Rambaut *et al.*, “A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
320 genomic epidemiology,” *Nat. Microbiol.*, vol. 5, no. 11, pp. 1403–1407, 2020.
- 321 [14] M. Bloemen *et al.*, “Fast detection of SARS-CoV-2 variants including Omicron using one-step
322 RT-PCR and Sanger sequencing,” *J. Virol. Methods*, vol. 304, no. March, p. 114512, 2022.
- 323 [15] E. Wollants, P. Maes, I. Thoelen, F. Vanneste, M. Rahman, and M. Van Ranst, “Evaluation of a
324 norovirus sampling method using sodium dodecyl sulfate/EDTA-pretreated chromatography
325 paper strips,” *J. Virol. Methods*, vol. 122, no. 1, pp. 45–48, 2004.
- 326 [16] P. Maes *et al.*, “Poliovirus sampling by using sodium dodecyl sulfate/EDTA-pretreated
327 chromatography paper strips,” *Biochem. Biophys. Res. Commun.*, vol. 325, no. 3, pp. 711–715,
328 2004.
- 329 [17] M. Rahman *et al.*, “Chromatography Paper Strip Method for Collection, Transportation, and
330 Storage of Rotavirus RNA in Stool Samples,” *J. Clin. Microbiol.*, vol. 42, no. 4, pp. 1605–1608,
331 2004.
- 332 [18] K. T. Zlateva, P. Maes, M. Rahman, and M. Van Ranst, “Chromatography paper strip sampling
333 of enteric adenoviruses type 40 and 41 positive stool specimens,” *Virol. J.*, vol. 2, pp. 1–5,
334 2005.
- 335 [19] ECDC, “Increase in severe acute hepatitis cases of unknown aetiology in children,” *Rapid Risk*

- 336 *Assess.*, no. April 28, pp. 1–19, 2022.
- 337 [20] J. M. Baker *et al.*, “Acute Hepatitis and Adenovirus Infection Among Children - Alabama,
338 October 2021-February 2022.,” *MMWR. Morb. Mortal. Wkly. Rep.*, vol. 71, no. 18, pp. 638–
339 640, 2022.
- 340 [21] K. Marsh *et al.*, “Investigation into cases of hepatitis of unknown aetiology among young
341 children, Scotland, 1 January 2022 to 12 April 2022,” *Eurosurveillance*, vol. 27, no. 15, pp. 1–7,
342 2022.
- 343 [22] B. Schweiger, I. Zadow, R. Heckler, H. Timm, and G. Pauli, “Application of a fluorogenic PCR
344 assay for typing and subtyping of influenza viruses in respiratory samples,” *J. Clin. Microbiol.*,
345 vol. 38, no. 4, pp. 1552–1558, 2000.
- 346 [23] A. Allard, B. Albinsson, and G. Wadell, “Rapid typing of human adenoviruses by a general PCR
347 combined with restriction endonuclease analysis,” *J. Clin. Microbiol.*, vol. 39, no. 2, pp. 498–
348 505, 2001.
- 349 [24] V. Gouvea *et al.*, “Polymerase chain reaction amplification and typing of rotavirus nucleic acid
350 from stool specimens,” *J. Clin. Microbiol.*, vol. 28, no. 2, pp. 276–282, 1990.
- 351 [25] T. Wawina-Bokalanga *et al.*, “Genetic diversity and evolution of SARS-CoV-2 in Belgium during
352 the first wave outbreak,” *bioRxiv*, p. 2021.06.29.450330, 2021.
- 353 [26] A. Nazario-Toole, H. M. Nguyen, H. Xia, D. N. Frankel, J. W. Kieffer, and T. F. Gibbons,
354 “Sequencing SARS-CoV-2 from antigen tests,” *PLoS One*, vol. 17, no. 2 February, pp. 1–8, 2022.
- 355
- 356
- 357
- 358

359 **TABLE**

360 **Table 1: Retrieval of viral material from rapid Ag tests**

	SAMPLE			ANTIGEN TEST				RESULT		
	virus	code	sample Ct	Name	use of buffer	region*	Δt^{**}	extract Ct	Sanger seq	WGS
archived Ag-RDT	SARS-CoV-2	CV-22-2069	UNK	Roche nasal	YES	zone d	3 mths	27.6	BA.1	ND
	SARS-CoV-2	X-22-0205	UNK	Newgene	YES	zone d	3 mths	ND	BA.2	BA.2
	SARS-CoV-2	CM-22-5857	18.6	AMP	YES	zone d	3 mths	26.7	BA.2	ND
	SARS-CoV-2	CM-22-5857	18.6	Orient	YES	zone d	3 mths	25.6	BA.2	ND
	SARS-CoV-2	CM-22-5857	18.6	Nadal	YES	zone d	3 mths	26.3	BA.2	ND
	Influenza A	BE-22-2238	24.6	AMP	YES	zone d	3 mths	35.4	H3N2	ND
	Influenza A	BE-22-2238	24.6	Orient	YES	zone d	3 mths	32.2	H3N2	ND
	Influenza A	BE-22-2238	24.6	Nadal	YES	zone d	3 mths	32.2	H3N2	ND
Evaluation of specimen preparation	SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone a	3 mths	17.3	BA.2	ND
	SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone b	3 mths	22.2	BA.2	ND
	SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone c	3 mths	19.6	BA.2	ND
	SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone d	3 mths	21.7	BA.2	ND
	SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone e	3 mths	22.6	BA.2	ND
	Influenza A	CM-22-6381	18.5	AMP	YES	zone a	3 mths	28.6	H3N2	NA
	Influenza A	CM-22-6381	18.5	AMP	YES	zone b	3 mths	29.9	H3N2	NA
	Influenza A	CM-22-6381	18.5	AMP	YES	zone c	3 mths	29.3	H3N2	NA
	Influenza A	CM-22-6381	18.5	AMP	YES	zone d	3 mths	30.6	H3N2	NA
	Influenza A	CM-22-6381	18.5	AMP	YES	zone e	3 mths	33.3	H3N2	NA
	SARS-CoV-2	CM-22-8672	16.5	Coris COVID-19	YES	zone d	24h	28.7	ND	ND
	SARS-CoV-2	CM-22-8672	16.5	Coris COVID-19	YES	PB zone d	24h	28.8	ND	ND
	SARS-CoV-2	CM-22-8702	18.5	Alltest	YES	PB zone a+d	24h	27	BA.2	BA.2
	SARS-CoV-2	CM-22-8702	18.5	Newgene	YES	PB zone a+d	24h	21.3	BA.2	BA.2
	SARS-CoV-2	CM-22-8702	18.5	FlowFlex	YES	PB zone a+d	24h	20.9	BA.2	BA.2
	SARS-CoV-2	CM-22-8702	18.5	Boson	YES	PB zone a+d	24h	26.5	BA.2	BA.2
	SARS-CoV-2	CM-22-6505	12.6	Roche nasal	YES	PB zone a+d	72h	32.5	Failed	ND
	SARS-CoV-2	CM-22-6505	12.6	Roche nasal	NO	PB zone a+d	72h	19.5	BA.2	BA.2
	SARS-CoV-2	CM-22-6516	20.6	Roche nasal	YES	PB zone a+d	72h	35.8	Failed	ND
	SARS-CoV-2	CM-22-6516	20.6	Roche nasal	NO	PB zone a+d	72h	28.8	BA.2	BA.2
	SARS-CoV-2	CM-22-3708	18.1	Roche nasal	YES	PB zone a+d	72h	32.9	Failed	ND
	SARS-CoV-2	CM-22-3708	18.1	Roche nasal	NO	PB zone a+d	72h	23.4	BA.4/BA.5	BA.5.1
	SARS-CoV-2	CM-22-4853	14.7	Roche nasal	YES	PB zone a+d	72h	33.3	Failed	ND
SARS-CoV-2	CM-22-4853	14.7	Roche nasal	NO	PB zone a+d	72h	22.0	BA.4/BA.5	BA.4	
SARS-CoV-2	CM-22-7973	15.8	Roche nasal	YES	PB zone a+d	72h	31.2	Failed	ND	
SARS-CoV-2	CM-22-7973	15.8	Roche nasal	NO	PB zone a+d	72h	22.9	BA.4/BA.5	BA.5.1	
Other viruses	AdV 40/41	F14284	UNK	Coris Gastro	YES	PB	24u	pos	AdV 41	NA
	AdV 40/41	F14298	UNK	Coris Gastro	YES	PB	24u	pos	AdV 41	NA
	Rotavirus	F14284	UNK	Coris Gastro	YES	PB	24u	pos	G2	NA
	Rotavirus	F14298	UNK	Coris Gastro	YES	PB	24u	pos	G2	NA

361

362 * region of test strip excised and used for extraction, as indicated in Figure 1

363 ** time between adding sample to Ag-RDT and nucleic acid extraction from the test strip

364 PB= punch biopsy; UNK = unknown; ND = Not Done; NA = not available

365 WGS results of poor quality (as indicated by Nextclade) are shaded in grey.

366

367 **FIGURE**

368

369

370

371

372




Figure 1: Opened cassette of an Orient Gene Influenza & COVID-19 Ag Combo Rapid Test, with dashed lines indicating the position of the sample windows (S) and result windows (R), displaying a positive test line (T) and control line (C). Regions excised for nucleic acid extraction (a-e) are delineated with dotted lines.